Skip to main content
Clinical Trials/DRKS00016741
DRKS00016741
Recruiting
Not Applicable

Exploratory study to assess frailty as a clinical marker for the plasma concentrations of the direct oral anticoagulants (Frailty-DOAK) - Frailty-DOAK

Agaplesion Bethanien Krankenhaus Geriatrisches Zentrum der Universität Heidelberg0 sites240 target enrollmentFebruary 20, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Frailty
Sponsor
Agaplesion Bethanien Krankenhaus Geriatrisches Zentrum der Universität Heidelberg
Enrollment
240
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 20, 2019
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Agaplesion Bethanien Krankenhaus Geriatrisches Zentrum der Universität Heidelberg

Eligibility Criteria

Inclusion Criteria

  • Age \=70 years
  • Regular intake of one of the direct oral anticoagulants dabigatran (Pradaxa®), rivaroxaban (Xarelto®), apixaban (Eliquis®) or edoxaban (Lixiana®) during the past \= 7 days
  • Mentally and physically able to participate in the study (as judged by a member of the study group)
  • Written informed consent

Exclusion Criteria

  • Insufficient knowledge of written and/or spoken German
  • Inability to give informed consent

Outcomes

Primary Outcomes

Not specified

Similar Trials